TREM2 and myeloid sarcoma: Moreover, MS patients treated with natalizumab, an immune-modulating drug, showed an improvement in the clinical course correlated with a significant decrease in the CSF soluble TREM2 (sTREM2) supporting the crucial role of microglia in the pathophysiology of multiple sclerosis [112].